JP Morgan Chase
MRSN

JP Morgan Chase’s Mersana Therapeutics MRSN Stock Holding History

JP Morgan Chase’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-18,192
Closed -$1.5M – 7628
2023
Q2 		$1.5M Buy
+18,192
New +$2.66M ﹤0.01% 3760

Other funds holding MRSN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

JP Morgan Chase's MRSN Position: Q1 2026 in Review

JP Morgan Chase sold out of Mersana Therapeutics (MRSN) in Q1 2026, closing a stake of 112 shares — an estimated $3.24K sold.

JP Morgan Chase first reported a position in MRSN in Q2 2017 and held it in 35 quarters. The position peaked at $6.39M in Q1 2024. 1 fund tracked by Wall St. Rank holds MRSN as of Q1 2026.

  • JP Morgan Chase reported no remaining Mersana Therapeutics position as of Q1 2026 after selling out during the quarter.
  • JP Morgan Chase sold 112 Mersana Therapeutics shares in Q1 2026, an estimated $3.24K.
  • JP Morgan Chase first reported a position in Mersana Therapeutics in Q2 2017 and held it in 35 quarters.
  • JP Morgan Chase's Mersana Therapeutics position peaked at $6.39M in Q1 2024.
  • 1 fund tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.